Stockreport

TRACON Announces Publication in Clinical Cancer Research of Phase 2 Clinical Data for TRC102, a DNA Damage Repair Inhibitor, in Recurrent Glioblastoma Patients

TRACON PHARMS INC  (TCON) 
Last tracon pharms inc earnings: 2/27 04:03 pm Check Earnings Report
US:NASDAQ Investor Relations: traconpharma.com
PDF Publication Highlights Activity of the Combination of TRC102 and Temodar (Temozolomide) in Patients who Progressed Following Initial Treatment with Surgical Resection, T [Read more]